Article
Loss of Payload Sensitivity and Other Mechanisms of Resistance to T-DXd in HER2-Mutant NSCLC: Implications for Subsequent Responsiveness to HER2 TKIs.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jun 2026
Nilsson Monique B, Le Xiuning, Poteete Alissa, Yu Xiaoxing, He Junqin, Huang Qian, Shibata Yuji, Liu Ximeng, Moran Cesar, Alizadeh Ash A, Diehn Maximilian, Wakelee Heather, Almanza Diego, Soltys Scott, Sugio Takeshi, Mutter Jurik, Kang Xiaoman, Wang Rui, Jun Soyeong, Esfahani Mohammad Shahrokh, Tran Hai, Xi Yuanxin, Hong Lingzhi, Huo Xiaofang, Kumar Ashwani, Ren Xiaoyang, Oguchi Kei, Minamiguchi Kazuhisa, Weipert Caroline M, Wang Jing, Kittler Ralf, Heymach John V
Abstract excerpt
INTRODUCTION: Effective therapies are needed for patients with NSCLC with HER2-mutant tumors who progress on the HER2 antibody-drug conjugate trastuzumab deruxtecan (T-DXd), a standard-of-care treatment. A greater understanding of mechanisms mediating acquired T-DXd resistance and whether these tumors could benefit from HER2 tyrosine kinase inhibitors (TKIs) is needed. METHODS: Using preclinical models of...
Topics
Join the communities discussing this publication.